Julie Levinson Werner and Sandra Halbing of Lowenstein Sandler discuss current DEI-related practices among businesses and ...

Merck & Co has said building its cardiovascular medicines ... by 40.8 meters from baseline at week 24 when added to stable background therapy for PAH. Patients who received sotatercept also ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities ...

Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. The Dow is a highly recognized and influential stock market index that ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, the host of Mad Money, recently ...

Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE ... t slow play the rollout of the Gardasil vaccine for no particular reason other than forget it… it’s China ...

Behind Winrevair, the most promising clinical-stage program in Merck's pipeline is a cholesterol drug tentatively named MK-0616. The company started a 17,000-patient phase 3 program to test MK ...